High efficacy of BPaL among patients infected with Mycobacterium tuberculosis lineage 1 in the Philippines

BACKGROUND: WHO recommends the bedaquiline–pretomanid–linezolid regimen with/without moxifloxacin (M) (BPaL/M) for the treatment of multidrug- or rifampicin-resistant TB. However, Mycobacterium tuberculosis (MTB) lineage 1 (L1) is less susceptible to pretomanid than other lineages, and there are lim...

Celý popis

Podrobná bibliografie

Hlavní autoři:	I. Flores, M.A.A. Tujan, R. Basilio, T.J.R. Dizon, D.R Lim, L.T. Reyes, R.V.A.G. Reyes, S. Rojas, A.K. Valencia, J.B. Capin, V. Mirtskhulava, A.G. Palparan, C. Cabalitan, P.J. Carpin, C. Malbacias, J.S. Lee, A. Gebhard, M. Quelapio, J. Timm
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	International Union Against Tuberculosis and Lung Disease (The Union) 2026-04-01
Edice:	IJTLD Open
Témata:	tuberculosis mdr/rr-tb treatment anti-tb drug resistance southeast asia
On-line přístup:	https://journals.theunion.org/content/ijtldo/3/4/226
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!